Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler  1     Andres Yarur  2     Uri Kopylov  3     Marielle Bassel  4     Neil Brett  4     Trevor Lissoos  5     claudia lopez  5     Athanasios Natsios  6     Sumit Saha     Christina Kifnidi     Dirk Demuth     Haridarshan Patel     Gerassimos J. Mantzaris    
1 University of British Columbia,Vancouver,Canada
2 Medical College of Wisconsin,Milwaukee,United States
3 Chaim Sheba Medical Center,Ramat Gan,Israel
4 Evidera,Montreal,Canada
5 Takeda Pharmaceuticals USA Inc,Deerfield,United States
6 Takeda Hellas S.A.,Athen

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing